IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Roger Cranwill who wrote (235)	12/14/1996 6:24:00 AM
From: I. Luttichuys	of 1762

Hello Roger, (0609 and still going strong) :o) I am not sure if what you are missing is the fact of the collaboration between Smith Kline and IDEC on CE9.1 or if you mean to ask for something else. Smith Kline has an agreement with IDEC under which IDEC recieves "milestone payments" from Smith Kline when certain targets/goals are achieved with respect to IDEC's Rheumatoid Arthritis therapy CE9.1. The completion of phase II for CE9.1 was one such milestone and generated the appropriate payment to IDEC. This therapy is shaping up in trials to be something just as exciting as C2B8. In terms of shear numbers of patients benefitted etc., it is definately a big thing. The potential is quite large. I often find myself thinking of Craig Weissenhutter's (the MD at the head of one of the trials for CE9.1) comment that the phase II patients were "literally dancing in the halls". I've been nervous during IDEC's recent decent but, I have to tell you, if there is a single comment that convinces me this is a keeper, that's it. I really do have to retire. If I have misinterpreted your question, let me know. I will get back tomorrow soonest. Have a good day, BENNETT

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next